---
schema_version: "secwatch.filing_event.v1"
accession: "0001439222-26-000071"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2026-04-29T23:59:59+00:00"
generated_at: "2026-05-15T01:41:54.330305+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Agios Q1 mitapivat revenue $20.7M; 242 AQVESME scrips; sCD sNDA plan in Q2

## Summary
- Worldwide mitapivat net revenue $20.7M in Q1 2026, up from $8.7M in Q1 2025.
- 242 AQVESME prescriptions for thalassemia by U.S. REMS-certified physicians as of March 31, 2026.
- Plans to submit mitapivat sNDA for sickle cell disease under accelerated approval pathway in Q2 2026.
- Net loss $99.1M in Q1 2026 vs $89.3M in Q1 2025.
- Cash and equivalents $1.0B as of March 31, 2026, down from $1.2B at Dec 31, 2025.

## SEC filing metadata
- accession: 0001439222-26-000071
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2026-04-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000071/0001439222-26-000071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000071/agio-20260429.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001439222-26-000071
- JSON: https://secwatch.observer/filing/0001439222-26-000071.json
- Plain text: https://secwatch.observer/filing/0001439222-26-000071.txt

## Key facts
- Earnings Releases
  AGIOS PHARMACEUTICALS, INC. reported the quarter ended March 31, 2026 results: net income $99.1 million.
  - Period: the quarter ended March 31, 2026
  - Net income: $99.1 million
  - Result: reported results
  source text: For the quarter ended March 31, 2026, net loss was $99.1 million, compared to net loss of $89.3 million for the quarter ended March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000071/0001439222-26-000071-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.